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Abstract 
Background: Vitamin D status has been hypothesized to protect against development of diabetic retinopathy via its 
anti-inflammatory and anti-angiogenic properties. Additionally, in vitro and in vivo studies suggest vitamin D favora-
bly influences blood pressure and blood glucose control, strong risk factors for diabetic retinopathy. We examined 
the association between vitamin D status and prevalent diabetic retinopathy in participants with diabetes from a 
population-based cohort.
Methods: Among participants in the Atherosclerosis Risk in Communities (ARIC) study with diabetes at visit 3 
(1993–1995), 1339 (906 Caucasians, 433 African Americans) had serum 25-hydroxyvitamin (25[OH]D) concentrations 
assessed at visit 2 (1989–1992) and nonmydriatic retinal photographs taken at visit 3. Dietary intake of vitamin D 
was assessed at visit 1 (1987–1989). Logistic regression was used to estimate odds ratios (ORs) and 95 % confidence 
intervals (CIs) for diabetic retinopathy by categories of season-adjusted 25(OH)D (<30 [referent], 30–<50, 50–<75 and 
≥75 nmol/L), by quartile of vitamin D intake (IU/day), and use of vitamin D or fish oil supplements (yes/no). P for trend 
was estimated using continuous 25(OH)D or vitamin D intake. ORs were adjusted for race, and duration of diabetes. 
We further adjusted for HBA1c and hypertension to examine if 25(OH)D influenced diabetic retinopathy via its effects 
on either glycemic control or blood pressure.
Results: ORs (95 % CIs) for retinopathy, adjusted for race and duration, were 0.77 (0.45–1.32), 0.64 (0.37–1.10), and 
0.39 (0.20–0.75), p for trend = 0.001, for participants with 25(OH)D of 30–<50, 50–<75, and ≥75 nmol/L, respectively. 
Further adjustment for hypertension minimally influenced results (data not show), but adjustment for HBA1c attenu-
ated the OR among those with 25(OH)D ≥75 (0.47 [0.23–0.96], p for trend = 0.030). No statistically significant associa-
tion was observed between vitamin D intake from foods or supplements and retinopathy.
Conclusions: 25(OH)D concentrations ≥75 nmol/L were associated with lower odds of any retinopathy assessed 
3 years later. We speculate this may be due in part to vitamin D’s influence on blood glucose control.
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Background
Diabetic retinopathy is a leading cause of blindness in 
adults aged 20–74  years in the United States. Among 
individuals with diabetes it has direct influences on qual-
ity of life and functional independence of aging, affecting 
~28.5  % of people with diabetes ≥40  years [1]. Modifi-
able nutritional factors may influence risk for diabetic 
retinopathy, but they have been relatively understudied 
in epidemiologic investigations [2]. Accumulating evi-
dence from some [3–13], but not all [14–23], epidemio-
logic studies suggest that vitamin D status may be a novel 
modifiable risk factor for diabetic retinopathy.
Vitamin D status is hypothesized to affect risk for retin-
opathy [4] due to its immunomodulatory properties [24] 
as chronic low grade inflammation is hypothesized to 
promote the development of retinopathy [25]. Vitamin D 
is also hypothesized to positively regulate hypertension 
[26] and blood glucose control [27], both of which are 
strong risk factors for retinopathy [28, 29].
Using data from the prospective, population-based 
Atherosclerosis Risk in Communities (ARIC) Study, 
we investigated associations between vitamin D status, 
assessed with the blood biomarker of serum 25-hydroxy-
vitamn D (25[OH]D), and prevalent diabetic retinopathy 
assessed from graded fundus photographs taken 3 years 
later among Caucasian and African American partici-
pants with primarily type 2 diabetes (n = 1339). 25(OH)
D reflects vitamin D from all sources (sunlight, diet and 
supplements). We hypothesized that individuals with 
higher 25(OH)D concentrations would have lower odds 
of retinopathy than participants with lower concentra-
tions. We examined the extent to which this associa-
tion was mediated by blood pressure or blood glucose 
control. We also explored associations between self-




The ARIC Study, a population-based prospective study 
[30], recruited participants from Forsyth County, North 
Carolina; Jackson, Mississippi; the northwestern suburbs 
of Minneapolis, Minnesota; and Washington County, 
Maryland. Eligible participants were between 45 and 
65  years of age at visit 1 (1987–1989) and intended to 
remain in the community in which they lived. All partici-
pants provided signed informed consent and the study 
protocol was approved by the institutional review boards 
at each ARIC study site and complies with the Helsinki 
Declaration as revised in 1983.
The present analyses use data collected at visits 1 
(1987–1989), 2 (1990–1992) and 3 (1993–1995). This 
study sample consists of Caucasian and African Ameri-
can participants who were classified as having diabetes 
(fasting blood glucose of 126 mg/dl or non-fasting blood 
glucose of 200 mg/dl; self-report of a diabetes diagnosis; 
or use of medication for diabetes in the 2 weeks prior to 
the visit) at study visit 3, had gradable retinal fundus pho-
tos at visit 3 and serum 25(OH)D measures at visit 2. This 
was a retrospective analysis to examine the association 
between serum draw at visit 2, but recently (2012–2013) 
analyzed for 25(OH)D concentrations, and the preva-
lence of diabetic retinopathy determined 3 years later at 
visit 3.
There were 15,792 participants enrolled at visit 1, of 
which 12,887 attended visit 3. We excluded 796 partici-
pants who did not consent to use of their data to study 
outcomes other than cardiovascular disease. Of the 
remaining 12,091 participants, 1899 were classified as 
having diabetes of whom 350 were missing data on retin-
opathy status (301 missing retinal photos and 49 with 
upgradable photos), 186 were missing serum 25(OH)D, 
8 identified as neither African American nor Caucasian, 
and 16 were missing data on pertinent covariates (glyco-
sylated hemoglobin A1c [HBA1c] or hypertension), pro-
viding a sample of 1339 participants. Analyses involving 
dietary vitamin D data had 1305 participants due to miss-
ing data on diet at visit 1.
Retinal photography
Diabetic retinopathy was determined from grading of 
fundus photographs taken at visit three of one randomly 
selected eye. Participants sat in a dark room for 5  min 
to allow for nonpharmocological pupil dilution [31]. 
One 45-degree nonmydriatic retinal photograph was 
taken with a Canon CR-45UAF nonmydriatic film cam-
era (Canon USA, Itasca, IL) and was centered to include 
the optic disc and the macula [31]. Fundus photographs 
were graded for the presence and severity of retinopathy 
at the University of Wisconsin Fundus Photograph Read-
ing Center using a standard grading system, the modi-
fied Arlie House classification scheme [32]. Twenty-one 
percent (n = 280 of 1339) of participants had any retin-
opathy, of which 207 had mild non-proliferative diabetic 
retinopathy (NPDR), 44 had moderate to severe NPDR, 
29 had proliferative diabetic retinopathy (PDR), and 3 
had macular edema.
Assessment of 25(OH)D
Vitamin D status was assessed by analyzing participants’ 
serum from fasting blood drawn at visit 2 for 25(OH)D 
concentrations (sum of 25[OH]D2 and 25[OH]D3) using 
liquid chromatography in tandem with high-sensitivity 
mass spectrometry (LC–MS) (Waters Alliance e2795; 
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Waters, Milford, MA, USA) at the Collaborative Stud-
ies Clinical Laboratory at Fairview University Medical 
Center (Minneapolis, MN), as previously described [33]. 
Serum samples were stored at −80  °C from 1990–1992 
until assessment of 25(OH)D from 2012 to 2013 [33]. The 
coefficient of variation, representing sample processing 
and laboratory error was 10.9  %. Differences in 25(OH)
D concentrations due to season were accounted for using 
local regression [34]. 25(OH)D was regressed on day of 
blood draw and was conducted separately for Caucasians 
and African Americans. Residuals were added back to the 
sample mean (60.1 and 47.4  nmol/L for Caucasian and 
African Americans, respectively) and the season-adjusted 
values were used in all further mentioned analyses.
Assessment of dietary and supplemental vitamin D intake
Dietary intake of vitamin D was assessed at visit 1 using 
a reliable and previously validated Willett 66-item semi-
quantitative food frequency questionnaire (FFQ) [35, 36]. 
At visit 3, participants were asked about their use of vita-
min D and fish oil supplements, as source of vitamin D. 
They were asked if they took fish oil (including omega-3 
fatty acids, eicosapentaenoic acid [EPA], and cod liver 
oil), the duration of use, and the dose per week. Partici-
pants were also asked whether or not they took vitamin 
D “on a regular basis,” but no additional information was 
asked on duration of use or dose. There were 48 partici-
pants who reported use of either vitamin D or fish oil at 
visit 3.
Assessment of additional participant characteristics
At each visit trained study personnel collected informa-
tion on participants’ demographic factors, health history, 
family health history, smoking, medication use and other 
potential risk factors for cardiovascular disease [30]. 
Blood collected at visit 2 [37] was assessed for serum 
glucose, HBA1c [38], hematocrit level [37], total plasma 
cholesterol, plasma triglyceride, low density lipoprotein 
(LDL), and high density lipoprotein (HDL) cholesterol 
concentrations [39].
Physical activity was assessed at visit 1 using a modi-
fied version [40] of the previously validated [41, 42] Bae-
cke questionnaire from which we created a composite 
physical activity index score ranging from 0 (low overall 
physical activity) to 6. Duration of diabetes was defined 
as <3 years, 3 to <6, and ≥6 years determined using data 
on self-reported diabetes diagnosis, fasting and non-
fasting blood glucose levels, and diabetes medication use 
collected at visits 1, 2 or 3. 25(OH)D concentrations and 
other covariate data used in these analyses were assessed 
at visit 2 with the exception of information on education, 
diet, physical activity (visit 1), and duration of diabetes 
(visit 3).
Statistical analysis
Guided by the Institute of Medicine, vitamin D status 
was defined using 25(OH)D concentrations (nmol/L) as 
deficient (<30), inadequate (>30 to ≤50), and using two 
categories within the concentrations considered adequate 
(>50 to <75 and ≥75) [43]. Participant characteristics and 
risk factors for retinopathy were examined by vitamin D 
status, as well as by presence of retinopathy (any versus 
none), using t-tests, ANOVAs or Chi square tests.
Logistic regression was used to estimate the odds ratios 
(ORs) and 95  % confidence intervals (95  % CIs) for any 
prevalent retinopathy (both NPDR and PDR) by vita-
min D status with the referent category of deficient sta-
tus (<30 nmol/L) []. We also estimate the odds of having 
PDR or macular edema (n = 31) among participants with 
25(OH)D ≥50 compared to <50 nmol/L. We had to apply 
the Firth bias-correction method for quasi-complete sep-
aration [44] due to the low number of outcomes. The ORs 
and 95  % CIs for retinopathy per 10  nmol/L difference 
in 25(OH)D are also presented and p-for trend analyses 
were conducted using 25(OH)D as a continuous variable.
Age, sex, race, education, duration of diabetes, smoking 
status, drinking status, ethanol intake, physical activity 
index score, body mass index (BMI), waist circumfer-
ence, hematocrit level, LDL, HDL, total cholesterol and 
triglyceride concentrations were assessed as potential 
confounders of the vitamin D status and retinopathy 
association. If these variables were associated with either 
vitamin D status or prevalent retinopathy at a p value of 
0.20 or less, we considered them for inclusion in the mul-
tivariable model. Using a forward, stepwise procedure, 
only potential confounders that changed the ORs ≥10 % 
were included in the adjusted model. The multivari-
able model was also adjusted for hypertension status and 
HBA1c (as a measure of blood glucose control) to exam-
ine whether these variables mediated the 25(OH)D and 
retinopathy association.
A sensitivity analysis was conducted restricting our 
sample to include only individuals defined as having 
diabetes at both visits 2 (when 25[OH]D was measured) 
and 3. We wanted to examine if the association between 
vitamin D status and retinopathy would change when the 
sample was limited to those who were diagnosed with 
diabetes when 25(OH)D measures were assessed. Effect 
modification of the vitamin D and retinopathy associa-
tion by age, sex, race, duration of diabetes and blood glu-
cose control was explored by adding an interaction term 
to our logistic regression models. A p value <0.10 for the 
interaction term was considered statistically significant.
Variation in 25(OH)D concentrations explained by 
dietary intake of vitamin D was estimated using linear 
regression with season-adjusted 25(OH)D concentra-
tions as the dependent variable and dietary vitamin D 
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intake as the independent variable. Adjusted ORs and 
95  % CIs for retinopathy in quartiles 2 through 4 (with 
quartile 1 as the referent) for dietary vitamin D intake 
(IU/day) and by category of reported frequency of con-
sumption of vitamin D rich foods (never consumers as 
the referent) were estimated. A p for trend using con-
tinuous vitamin D intake or frequency of consumption, 
respectively, was estimated. We also estimated the odds 
of retinopathy in those who reported using vitamin D or 
fish oil supplements.
Results
Seven percent of participants had deficient vitamin 
D status (25[OH]D  <  30  nmol/L) and 59 and 16  % had 
adequate status with 25(OH)D concentrations ≥50 and 
≥75  nmol/L, respectively (Table  1). Participants with 
adequate (≥75 nmol/L) compared to deficient vitamin D 
status were less likely to have retinopathy, be women, be 
from Jackson, MS, and have graduated high school, and 
they were more likely to be older and Caucasian. There 
was a greater proportion of former (compared to never 
or current) smokers with adequate versus deficient sta-
tus. Individuals with adequate status had greater vitamin 
D intake, smaller waist circumferences, were less likely 
to be obese, and more likely to be physical active. On 
average their systolic blood pressure, HDL, glucose, and 
HBA1c were lower, and their hematocrit and triglycerides 
were higher. Those with adequate status were also less 
likely to have used insulin in the last 2 weeks.
Of the 1339 diabetic participants, 21 % (n = 280) had 
DR. In crude analyses, individuals with 25(OH)D con-
centrations 50 to <75 and ≥75  nmol/L had lower odds 
of retinopathy than deficient individuals (Table 2). Only 
adjustment for race and duration of diabetes changed 
the odds ratio greater than 10 % and were included in the 
multivariable model. Adjustment for age or BMI, a strong 
predictor of 25(OH)D concentrations, had no additional 
influence on the model and thus was not adjusted for 
in these analyses. After adjustment for these covariates 
there was a significant 61 % lower odds of retinopathy for 
those with 25(OH)D concentrations ≥75  nmol/L, with 
a significant p for trend of 0.001 and a 13 % lower odds 
of retinopathy with each additional 10 nmol/L in serum 
25(OH)D concentrations. Further adjustment for HBA1c 
attenuated the association, but did not remove statistical 
significance. The odds of participants having proliferative 
diabetic retinopathy or macular edema among those with 
25(OH)D ≥50 nmol/L (19 out of 789 at risk) compared to 
those with 25(OH)D <50 nmol/L (12 out of 550 at risk) 
was 1.48 (0.70–3.12) adjusted for race, duration, HBA1c 
and hypertension status. The adjusted odds ratio per 
10 nmol/L difference in 25(OH)D was 1.07 (0.89–1.29), p 
for trend =0.473.
The observed lower odds of retinopathy among par-
ticipants with adequate compared to deficient vitamin 
D status remained regardless of age, sex, race, duration 
of diabetes and glycemic control, except for observa-
tions in the youngest age group (54  years and younger) 
(Table 3). There were not statistically significant interac-
tions. A sensitivity analysis removing participants who 
were not classified as having diabetes at visit 2 (n = 336), 
when 25(OH)D concentrations were measured, did not 
substantially change the main findings. The odds of retin-
opathy in participants with 25(OH)D ≥75 compared to 
<30  nmol/L was 0.43 (0.21–0.88), p for trend  =  0.005 
after adjustment for race and duration and 0.54 (0.25–
1.15), p for trend  =  0.055 with further adjustment for 
HBA1c and hypertension status.
Dietary vitamin D intake of vitamin D from foods 
accounted for 1  % of the between person variation in 
25(OH)D concentrations in this sample. No statisti-
cally significant associations were found between vita-
min D intake from foods and retinopathy (Additional 
file 1: Table S1). Intake of 1 serving (3–5 oz) of dark fish 
>1/week compared to never was associated with a 68 % 
lower odds of retinopathy with a p for continuous trend 
of 0.060. Further adjustment by intake of omega-3 poly-
unsaturated fatty acids (PUFAs) did not attenuate this 
association (data not shown). The odds of retinopathy 
among vitamin D and fish oil supplement users com-
pared to nonusers was 0.63 (0.25–1.64) with adjustment 
for race, duration of diabetes, HBA1c, and hypertension 
status.
Discussion
We observed a dose–response association between 
25(OH)D concentrations and diabetic retinopathy, sug-
gesting that individuals with higher 25(OH)D con-
centrations have lower odds of prevalent retinopathy, 
primarily NPDR. No statistically significant associa-
tion was observed between 25(OH)D and severe disease 
(PDR or macular edema) although the number of cases 
was small (n = 31). A protective association with intake 
of vitamin D from all foods combined was not observed. 
Assessment of dietary vitamin D intake, as measured, 
does not likely reflect or enhance vitamin D status as we 
found vitamin D intake only explained a minimal amount 
of the between person variation in 25(OH)D concen-
trations in this sample. We did observe that frequent 
consumption (>1 time per week) of dark fish compared 
to never eating this type of fish was associated with a 
decreased odds for retinopathy. Fish are a rich source of 
vitamin D as well as omega-3 PUFAs (eicosapentaenoic 
and docosahexaenoice acid). omega-3 have anti-inflam-
matory properties [45], but adjustment for intake of 
omega-3 PUFAs did not confound this association.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 7 of 11Millen et al. Cardiovasc Diabetol  (2016) 15:128 
Previous research on the association between vitamin 
D status and diabetic retinopathy has predominantly 
focused on samples of individuals with type 2 diabe-
tes [3–8, 11–17, 19, 21–23], similar to ARIC, with some 
research focused on individuals with type 1 diabetes [9, 
10, 18, 20]. A number of studies have compared 25(OH)
D concentrations between groups of individuals with and 
without diabetic retinopathy in case–control designs [3, 
11, 13, 17, 22] with a protective association of 25(OH)D 
on prevalent retinopathy found in three studies [3, 11, 
13]. The majority of other studies consist of cross-sec-
tional designs recruiting participants from clinical set-
tings [5, 6, 9, 10, 12, 14, 15, 19, 21, 23] with half of these 
studies supporting a protective association of vitamin 
D with retinopathy [5, 6, 9, 10, 12]. All noted studies 
recruited participants with diabetes from clinic settings, 
perhaps limiting the generalizability of study findings. 
Other limitations include small sample sizes (n ≤ 300 for 
samples of individuals with diabetes) [5, 10, 11, 13–15, 
17, 23], lack of multivariate adjusted analysis [14, 17], 
inclusion of strong determinants of 25(OH)D concentra-
tions in multivariable models which may result in overad-
justment [20], and assessment of retinopathy status from 
ophthalmologist examination rather than from standard-
ized grading of retinal fundus photographs [3, 5, 11–15, 
17, 19, 21–23].
Results from nationally representative surveys [4, 6] 
comprised primarily of individuals with type 2 diabetes 
have supported a protective association between retin-
opathy status and 25(OH)D concentrations; however a 
population-based cohort [20] of individuals with type 1 
diabetes has not. Strengths of these studies include the 
use of graded, retinal photographs, adjustment for other 
confounding factors, and large sample sizes (~500 + par-
ticipants). These cross-sectional studies cannot establish 
temporality of the vitamin D and retinopathy association, 
similar to the present study.
Only three studies to date have examined prospec-
tive associations between vitamin D status and risk of 
retinopathy [8, 16, 18]. No statistically significant asso-
ciation was observed between 25(OH)D concentra-
tions and the 26-year incidence of either background or 
proliferative retinopathy among 220 patients with type 
1 diabetes attending a diabetes center [18] or with the 
5-year incidence or progression of retinopathy in the 
Veterans Affairs Diabetes Trial (n = 955) [16]. A recent 
study of 9524 participants with type 2 diabetes from the 
Fenofibrate intervention and Event Lowering Diabetes 
(FIELD) Trial were followed for development microvas-
cular complications, including retinopathy determined 
by on-study laser treatment (not fundus photography). 
[8] They observed a significant 13  % (p  =  0.03) lower 
odds of microvascular complications with each baseline 
50  nmol/L difference in 25(OH)D. Further adjustment 
of the multivariable model for HBA1c, physical activ-
ity or seasonal variability attenuated the association and 
removed its statistical significance. In our study, the asso-
ciation between vitamin D status and retinopathy was 
also attenuated after adjustment for glycemic control. 
It is unclear whether adjustment for HBA1c confounds 
the observed association or results in over adjustment 
because vitamin D protects against retinopathy via its 
influence on glycemic control.
Vitamin D is proposed to have a role in ocular health. 
Expression of the vitamin D receptor (VDR) in the 
retina [46] and in human cultured retinal endothelial 
Table 2 Crude and adjusted OR and 95 % CIs for the diabetic retinopathy by vitamin D status among Caucasian and Afri-
can American ARIC study participants classified as having diabetes and having gradable eye photos at visit 3 (1993–95), 
and available serum 25(OH)D concentrations at visit 2 (1990–92) (N = 1339)
* p for trend calculated using season adjusted serum 25(OH)D as a continuous variable
a Model 1: adjusted for race and duration of diabetes
b HBA1c was entered as a continuous variable; hypertension status is defined as in Table 1
Model Vitamin D status defined by serum 25(OH)D concentrations (nmol/L)




28/96 111/454 115/577 26/212
Crude model 1 0.79 (0.48–1.28) 0.61 (0.37–0.98) 0.34 (0.19–0.62) <0.001 0.85 (0.79–0.92)
Model 1a 1 0.77 (0.45–1.32) 0.64 (0.37–1.10) 0.39 (0.20–0.75) 0.001 0.87 (0.81–0.95)
Model 1 + HBAb1c 1 0.81 (0.45–1.45) 0.70 (0.39–1.27) 0.47 (0.23–0.96) 0.030 0.91 (0.83–0.99)
Model 1 + hypertension 
statusb
1 0.77 (0.45–1.32) 0.63 (0.37–1.09) 0.38 (0.20–0.75) 0.001 0.87 (0.81–0.95)
Model 1 + HBA1c + hyper-
tension status
1 0.81 (0.45–1.46) 0.70 (0.39–1.25) 0.47 (0.23–0.96) 0.026 0.91 (0.83–0.99)
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Table 3 Adjusted OR and  95  % CIs for  diabetic retinopathy by  vitamin D status stratified by  age, sex, race, duration 
of diabetes, and HbA1c levels among Caucasian and African American ARIC study participants classified as having dia-
betes, with  gradable eye photo at  visit 3 (1993–95), and  available serum 25(OH)D concentrations at  visit 2 (1990–92) 
(N = 1339)
Vitamin D status assessed with serum 25(OH)D concentrations (nmol/L)




≥75 adequate p trend* Continuous, 
per 10 nmol/L
Age group
 47 to 54 years (n = 471)
   #with DR/# in group 8/40 40/172 33/195 10/64
  Adjusted OR (95 % CI)a 1 1.20 (0.42–3.44) 0.90 (0.31–2.64) 1.44 (0.39–5.25) 0.800 1.02 (0.87–1.20)
 55–59 years (n = 356)
   #with DR/# in group 6/26 24/124 30/147 7/59
  Adjusted OR (95 % CI) 1 0.84 (0.23–3.04) 1.12 (0.31–4.08) 0.88 (0.19–4.07) 0.686 0.96 (0.80–1.16)
 60–64 years (n = 332)
  #with DR/# in group 9/19 30/103 35/149 5/61
  Adjusted OR (95 % CI) 1 0.43 (0.14–1.36) 0.39 (0.12–1.20) 0.10 (0.02–0.45) 0.011 0.80 (0.68–0.95)
 65 to 68 years (n = 180)
  #with DR/# in group 5/11 17/55 17/86 4/28
  Adjusted OR (95 % CI) 1 0.64 (0.13–3.09) 0.38 (0.08–1.81) 0.27 (0.04–1.69) 0.203 0.86 (0.68–1.08)
 p for interaction 0.372
Sex
 Men (n = 629)
  #with DR/# in group 5/18 38/161 64/323 12/127
  Adjusted OR (95 % CI) 1 0.67 (0.19–2.36) 0.52 (0.15–1.79) 0.23 (0.06–0.89) 0.019 0.85 (0.75–0.97)
 Women (n = 710)
   #with DR/# in group 23/78 73/293 51/254 14/85
  Adjusted OR (95 % CI) 1 0.80 (0.41–1.59) 0.68 (0.33–1.38) 0.78 (0.31–1.97) 0.262 0.93 (0.82–1.05)
 p for interaction 0.320
Race
 Caucasian (n = 906)
  #with DR/# in group 10/38 55/249 73/428 23/191
  Adjusted OR (95 % CI) 1 0.72 (0.29–1.81) 0.52 (0.21–1.28) 0.40 (0.15–1.07) 0.072 0.91 (0.82–1.01)
African American (n = 433)
  #with DR/# in group 18/58 56/205 42/149 3/21
  Adjusted OR (95 % CI) 1 0.89 (0.42–1.89) 0.98 (0.45–2.16) 0.45 (0.10–2.15) 0.268 0.91 (0.77–1.08)
 p for interaction 0.555
Duration of diabetes,
 <6 years (n = 593)
 #with DR/# in group 5/44 13/195 15/256 1/98
 Adjusted OR (95 % CI) 1 0.53 (0.17–1.60) 0.48 (0.16–1.45) 0.08 (0.01–0.72) 0.014 0.77 (0.62–0.95)
 ≥6 years (n = 746)
 #with DR/# in group 23/52 98/259 100/321 25/114
 Adjusted OR (95 % CI) 1 0.99 (0.50–1.95) 0.84 (0.43–1.65) 0.68 (0.30–1.52) 0.219 0.94 (0.85–1.04)
p for interaction 0.417
HBA1c levels
  ≤7 % (adequate control) (n = 756)
  #with DR/# in group 5/47 21/241 16/326 4/142
  Adjusted OR (95 % CI) 1 0.75 (0.26–2.13) 0.44 (0.15–1.29) 0.26 (0.06–1.07) 0.091 0.86 (0.73–1.02)
  >7 % (inadequate control) (n = 583)
  #with DR/# in group 23/49 90/213 99/251 22/70
  Adjusted OR (95 % CI) 1 0.93 (0.47–1.83) 0.89 (0.45–1.77) 0.65 (0.28–1.51) 0.163 0.93 (0.83–1.03)
p for interaction 0.290
* p for trend calculated using serum 25(OH)D as a continuous variable
a Model adjusted for race, duration of diabetes, HbA1c (continuous), and hypertension status. Strata of HbA1c are further adjusted for continuous levels of HBA1c
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cells [47], support this hypothesis. Further, the enzyme 
1-α-hydroxylase, responsible for synthesis of 1,25(OH)2D, 
is expressed in the retina suggesting a local action of the 
hormone calcitriol (1,25(OH)2D) in the eye [46].
In vitro studies [48] and animal models of diabetes [49] 
suggest that chronic low grade inflammation plays a role 
in the development of diabetic retinopathy; however, evi-
dence of associations between biomarkers of systemic 
inflammation and diabetic retinopathy in epidemiologic 
studies still remains inconclusive [50]. High blood glu-
cose is thought to increase adhesion of leukocytes to 
microvascular endothelial cells leading to cell damage, 
impaired blood flow [49, 51], and consequential retin-
opathy lesions [52, 53]. We hypothesize that vitamin D 
may down-regulate a localized, ocular, pro-inflammatory 
state by suppressing pro-inflammatory cytokines and 
other toxic agents [24]. This is supported by a study in 
cultured endothelial cells showing that vitamin D reduces 
the damaging effects of advanced glycation end products 
[54].
The VDR is expressed in human pancreatic beta-cells 
[55] and the human insulin receptor gene’s promoter has 
a vitamin D response element [56], suggesting a possible 
role in blood glucose control. To date, in  vitro cell cul-
ture and animal model studies of diabetes examining the 
effect of 1,25(OH)2D on beta cell function, insulin recep-
tor gene expression, and glucose uptake are inconclu-
sive [57]. A recent meta-analysis suggests no association 
between randomized controlled vitamin D supplementa-
tion trials and glucose homeostasis or diabetes preven-
tion; however, this study could not make conclusions 
with respect to the effect of long-term supplementation 
and micro- or macro-vascular complications of diabetes 
[58].
Our study is limited by its cross-sectional design and 
therefore cannot determine the temporality of this asso-
ciation between vitamin D and retinopathy. We are also 
limited by the availability of retinal photographs taken 
of one field from only one eye. There may be misclassi-
fication of endpoints ascertained at visit 3. However, as 
the photographed eye was chosen randomly, we would 
expect nondifferential misclassification of our endpoint 
which would bias our observed risk estimates toward 
the null. We also could not adequately explore the asso-
ciation between vitamin D and proliferative retinopathy 
due to the small number of participants with this out-
come. Vitamin D has been shown to inhibit angiogen-
esis in an animal model of oxygen-induced ischemic 
retinopathy [59] and inhibit vascular endothelial growth 
factor and transforming growth factor-β1 expression 
in retinal tissues of experimentally induced diabetes in 
rats [60]. We also did not have data on sunlight expo-
sure, and thus were unable to examine the association 
between vitamin D and diabetic retinopathy inclusive of 
all relevant sources contributing to circulating 25(OH)D 
concentrations.
Our study’s strength include a well-defined population 
of individuals with diabetes and availability of numerous, 
measured covariates that we could adjust for as potential 
confounding factors, although we realize that residual 
confounding may exist. Our study was population-based 
and is most generalizable to individuals with type 2 dia-
betes who comprised the majority of our sample. We 
were able to examine this association in both Caucasians 
and African Americans, showing that associations did 
not vary by race. We had retinal photographs, graded in 
a standardized fashion, to assess retinopathy and 25(OH)
D and assessed using LC–MS, the gold standard for vita-
min D assessment [61], with standardized, quality con-
trol measures taken. Our study contributes to the body 
of evidence supporting a protective, association between 
25(OH)D and prevalent diabetic retinopathy that is con-
sistent across racial groups.
Conclusions
In conclusion, adequate vitamin D status, 25(OH)D con-
centrations ≥75 nmol/L, may be associated with reduced 
odds of diabetic retinopathy. We speculate that the influ-
ence of vitamin D on diabetic retinopathy may be, in 
part, via its influence on blood glucose control.
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